Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond

Surgical Oncology Clinics of North America

Volumn 11, Issue 3, 2002, Pages 571-588

  Warren, Robert S ^a   Kirn, David H ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Kirn Oncology Consulting   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CN 706; CN 787; FLUOROURACIL; FOLINIC ACID; G 207; GENE PRODUCT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; NV 1020; ONYX 015; PROTEIN ADP53; PROTEIN P53; REOLYSIN; SCH 58500; UNCLASSIFIED DRUG;

ADENOVIRUS; CANCER LOCALIZATION; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; FEVER; GENE CONSTRUCT; GENE LOSS; GENE MUTATION; GENE REPLICATION; HEPATIC ARTERY; HUMAN; INJECTION PAIN; LIVER CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; NAUSEA; NONHUMAN; PROTEIN FUNCTION; PROTEIN TARGETING; REGIONAL PERFUSION; REVIEW; THROMBOCYTOPENIA; TRANSAMINITIS; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, P53; GENETIC VECTORS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MAXIMUM TOLERATED DOSE; VIRAL VACCINES;

EID: 0036660955     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00043-1     Document Type: Review

References (53)

1. Abbruzzese J, Evans D, Rich T. Cancer of the pancreas. In: DeVita V, Hellman S, Rosenberg S, editors. Cancer: Principles and Practice of Oncology. 5th edition. Philadelphia: Lippincott-Raven; 1997. p. 1054-86.
2. Kemeny N, Huang Y, Cohen A, et al. Hepatic arterial infusion of chemotherapy following resection of hepatic metastases from colorectal cancer. N Engl J Med 1999;341:2039-48.
3. Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.
4. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
5. Scheffner M, Werness BA, Huibregtse JM, et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
6. Pomerantz J, Schreiber-Agus N, Liegeois NJ, et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998;92:713-23.
7. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92:725-34.
8. Rodrigues NR, Rowan A, Smith ME. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990;87:7555-9.
9. McCormick F. Cancer gene therapy: Fringe or cutting edge? Nature Rev Cancer 2001;1:130-41.
10. Kozarsky KF, Wilson JM. Gene therapy: Adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503.
11. Roth J, Cristiano RJ. Gene therapy for cancer: What have we done and where are we going? J Natl Cancer Inst 1997;89:21-39.
12. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat Med 2001;7:781-7.
13. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science New Series 1996;274(5286):373-6.
14. Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nat Med 2000;6:1134-9.
15. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000;19:2-12.
16. Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999;10:1721-33.
17. Yu D, Sakamoto G, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999;59:1498-504.
18. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial. Cancer Res 2000;60:6359-66.
19. Vasey P, Shulman L, Gore M, et al. Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian carcinoma [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:1512.
20. Heise C, Williams A, Xue S, et al. Intravenous administration of ONYX-015, a selectively-replicating adenovirus, induces antitumoral efficacy. Cancer Res 1999;59:2623-8.
21. Marshall E. Clinical trials: Gene therapy death prompts review of adenovirus vector. Science 1999;286:2244-45.
22. Beardsley T. Gene therapy setback. Sci Am 2000;282:36-7.
23. Jenks S. Gene therapy death - Everyone has to share in the guilt. J Natl Cancer Inst 2000;92:98-100.
24. Miller H. Letter to the editor. Science 2000;287:591.
25. Barker DD, Berk AJ. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987;156:107-21.
26. Heise C, Sampson JA, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
27. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-6.
28. Harada J, Berk A. p53-independent and -dependent requirements for E1B-55kD in adenovirus type 5 replication. J Virol 1999;73:5333-44.
29. Rothmann T, Hengstermann A, Whitaker NJ. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol 1998;72:9470-8.
30. Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol 1998;72:9479-90.
31. Rogulski K, Freytag S, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000;60:1193-6.
32. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015). Nat Med 2000;6:1128-33.
33. Kirn D, Hermiston T, McCormick F. ONYX-015: Clinical data are encouraging. Nat Med 1998;4:1341-2.
34. Kirn D, Nemunaitis J, Ganly I. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proceedings of the American Society of Clinical Oncology 1998;17:391a.
35. Khuri F, Nemunaitis J, Ganly I, et al. A controlled trial of Onyx-015, an E1B gene-deleted adenovirus, in combination with chemotherapy in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
36. Kirn DH, Khuri F, Ganly I, et al. A phase II trial of ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Proceedings of the American Society of Clinical Oncology 1999;18:1505.
37. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
38. Reid A, Galanis E, Abbruzzese J, et al. A phase I/II trial of ONYX-015 administered by hepatic artery infusion to patients with colorectal carcinoma. EORTC-NCI-AACR Meeting on Molecular Therapeutics of Cancer, Amsterdam 1999.
39. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 1994;5:1079-88.
40. Mujoo K, Maneval D, Anderson S, et al. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996;12:1617-23.
41. Nemunaitis J, Swisher SG, Timmons T, et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000;18:609-22.
42. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther 2001;8:1618-26.
43. Reid T, Galanis E, Abbruzzese J, et al. Hepatic artery infusion of Onyx-015, a replication-selective adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: A phase I/II clinical trial [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:953.
44. Habib N, Sarraf C, Mitry R. EIB-deleted adenovirus (d11520) gene therapy for patients with primary and secondary liver tumors. Hum Gene Ther 2001;12:219-26.
45. Nemunaitis J, Cunningham C, Randlev B, et al. A phase I dose escalation trial of intravenous infusion with a replication-selective adenovirus, dl 1520, in patients with refractory cancer [abstract]. Proceedings of the American Society of Clinical Oncology 2000;19:724.
46. Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998;16:1479-89.
47. Brusilow S, Maestri N. Urea cycle disorders: Diagnosis, pathophysiology and therapy. Adv Pediatr 1996;43:127-70.
48. Coffey M, Strong J, Forsyth P, et al. Reovirus therapy of tumors with activated ras pathway. Science 1998;282:1332-4.
49. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
50. Roelvink P, Mi G, Einfeld D, et al. Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae. Science 1999;286:1568-71.
51. Suzuki K, Fueyo J, Krasnykh V, et al. A replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin Cancer Res 2001;7:120-6.
52. Doronin K, Toth K, Kuppuswamy M, et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol 2000;74:6147-55.
53. Hermiston T. Gene delivery from replication-selective viruses: Arming guided missiles in the war against cancer. J Clin Invest 2000;105:1169-72.